此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

一项评估常规临床实践中哮喘患者疾病特征和结局的研究 (AIRITY)

2026年11月4日 更新者:Sanofi

一项混合横断面和前瞻性研究,旨在评估哮喘患者在真实世界中的患者特征、疾病负担、疾病控制、表型、内型及结局

The main aim of the study to describe the characteristics of participants with asthma across the spectrum of disease severity, including sociodemographic and clinical characteristics, treatment and disease burden, biomarkers, and both disease-specific and generic health-related quality of life.

The study consists of two parts: a cross-sectional study, and a prospective follow-up evaluate changes in disease trajectories in participants with asthma.

研究概览

研究类型

观察性的

注册 (估计的)

2500

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:Trial Transparency email recommended-Toll free for US & Canada
  • 电话号码:6 800-633-1610
  • 邮箱:Contact-US@sanofi.com

学习地点

    • Alberta
      • Calgary、Alberta、加拿大、T3R 1W7
        • 招聘中
        • Investigational Site Number: 124203
    • Ontario
      • Windsor、Ontario、加拿大、N8X 2G1
        • 招聘中
        • Investigational Site Number: 124201
    • Quebec
      • Trois-Rivières、Quebec、加拿大、G8T7A1
        • 招聘中
        • Investigational Site Number: 124204
    • Bayern (Bavaria)
      • München、Bayern (Bavaria)、德国、85039
        • 招聘中
        • Investigational Site Number: 276503
    • North Rhine-Westphalia
      • Bonn、North Rhine-Westphalia、德国、53119
        • 招聘中
        • Investigational Site Number: 276505
    • Saxony
      • Hohenstein-Ernstthal、Saxony、德国、09337
        • 招聘中
        • Investigational Site Number: 276501
    • Schleswig-Holstein
      • Schleswig、Schleswig-Holstein、德国、24837
        • 招聘中
        • Investigational Site Number: 276502
      • Niigata、日本
        • 招聘中
        • Investigational Site Number: 392707
    • Fukuoka
      • Kitakyushu-Shi、Fukuoka、日本、802-0083
        • 招聘中
        • Investigational Site Number: 392705
    • Kagawa-ken
      • Takamatsu、Kagawa-ken、日本、761-8073
        • 招聘中
        • Investigational Site Number: 392702
    • Saga-ken
      • Saga、Saga-ken、日本、849-8501
        • 招聘中
        • Investigational Site Number: 392711
    • Tokyo
      • Bunkyo-ku、Tokyo、日本、113-8431
        • 招聘中
        • Investigational Site Number: 392710
      • tabashi City、Tokyo、日本、173-8610
        • 招聘中
        • Investigational Site Number: 392709
    • Brittany Region
      • Brest、Brittany Region、法国、29200
        • 招聘中
        • Investigational Site Number: 250603
    • Occitanie
      • Lunel、Occitanie、法国、34400
        • 招聘中
        • Investigational Site Number: 250612
      • Toulouse、Occitanie、法国、31059
        • 招聘中
        • Investigational Site Number: 250607
    • Pays de la Loire Region
      • La Roche-sur-Yon、Pays de la Loire Region、法国、85000
        • 招聘中
        • Investigational Site Number: 250613
    • Île-de-France Region
      • Argenteuil、Île-de-France Region、法国、95100
        • 招聘中
        • Investigational Site Number: 250616
      • Créteil、Île-de-France Region、法国、94010
        • 招聘中
        • Investigational Site Number: 250609
    • Alabama
      • Bessemer、Alabama、美国、35022
        • 招聘中
        • Trinity Clinical Research, LLC - Bessemer - Site Number: 840150
    • Arizona
      • Chandler、Arizona、美国、85224
        • 撤销
        • Chandler Clinical Trials - Site Number: 840106
      • Mesa、Arizona、美国、85206
        • 主动,不招人
        • Del Sol Research Management, LLC - Mesa - Site Number: 840123
      • Scottsdale、Arizona、美国、85254
        • 招聘中
        • Orso Health - Scottsdale - Site Number: 840133
      • Sun City、Arizona、美国、85351
        • 主动,不招人
        • Sun City Clinical Trials - Elite - Site Number: 840120
    • California
      • California City、California、美国、91107
        • 主动,不招人
        • FOMAT - Huntington Asthma & Allergy Center - Site Number: 840158
      • La Palma、California、美国、90623
        • 主动,不招人
        • Imax Clinical Trials - Site Number: 840109
      • Los Angeles、California、美国、90017
        • 主动,不招人
        • Downtown LA Research - Site Number: 840161
      • Newport Beach、California、美国、92663
        • 主动,不招人
        • Newport Native MD, Inc. - Site Number: 840101
      • Pasadena、California、美国、91101
        • 主动,不招人
        • Pasadena Clinical Trials - Site Number: 840116
      • Tarzana、California、美国、91356
        • 撤销
        • Valiance Clinical Research (JPJ Research) - Site Number: 840135
      • Walnut Creek、California、美国、94598
        • 主动,不招人
        • Clinical Research of California - Site Number: 840145
    • Florida
      • Altamonte Springs、Florida、美国、32701
        • 主动,不招人
        • Cornerstone Research Institute, LLC - Site Number: 840152
      • Boca Raton、Florida、美国、33431
        • 主动,不招人
        • 3SYNC Research - Boca Raton - Site Number: 840148
      • Brandon、Florida、美国、33511
        • 主动,不招人
        • Meris Clinical Research - Site Number: 840167
      • Greenacres City、Florida、美国、33467
        • 主动,不招人
        • Finlay Medical Research - Site Number: 840107
      • Miami、Florida、美国、33126
        • 主动,不招人
        • EMDA Clinical Research - Site Number: 840113
      • Miami、Florida、美国、33126
        • 主动,不招人
        • Finlay Medical Research - Miami - Site Number: 840110
      • Miami、Florida、美国、33130
        • 主动,不招人
        • Care Research Inc. - Site Number: 840103
      • Miami、Florida、美国、33142
        • 主动,不招人
        • L&A Morales Healthcare, Inc - Site Number: 840102
      • Miami、Florida、美国、33145
        • 主动,不招人
        • MedOne Clinical Research - Site Number: 840122
      • Miami、Florida、美国、33155
        • 主动,不招人
        • D&H National Research Centers INC - Site Number: 840128
      • Miami、Florida、美国、33173
        • 主动,不招人
        • Research Institute Of South Florida - Site Number: 840149
      • Miami、Florida、美国、33174
        • 主动,不招人
        • Valencia Medical & Research Center, Corp - Site Number: 840153
      • Miami、Florida、美国、33186
        • 主动,不招人
        • Correa Research Center, Inc. - Site Number: 840141
      • Miami Gardens、Florida、美国、33014
        • 主动,不招人
        • Pro Care Research Center - Site Number: 840143
      • Miami Lakes、Florida、美国、33014
        • 主动,不招人
        • 3SYNC Research - Miami Lakes - Site Number: 840146
      • Miami Lakes、Florida、美国、33014
        • 主动,不招人
        • Deluxe Health Center - Site Number: 840117
      • Miami Lakes、Florida、美国、33016
        • 主动,不招人
        • MedQuest Translation Sciences, LLC - Site Number: 840162
      • North Miami Beach、Florida、美国、33169
        • 主动,不招人
        • Biscayne Clinical Research - Site Number: 840157
      • Palm Springs、Florida、美国、33406
        • 主动,不招人
        • CTMD Research, Inc - Site Number: 840147
      • Plantation、Florida、美国、33317
        • 主动,不招人
        • Edward Jenner Research Group, LLC - Site Number: 840169
      • Port Saint Lucie、Florida、美国、34986
        • 主动,不招人
        • Mark J. Pamer D.O., LLC - Site Number: 840121
      • Tamarac、Florida、美国、33321
        • 主动,不招人
        • TBC Research Corp - Site Number: 840132
      • Tampa、Florida、美国、33613
        • 主动,不招人
        • Avita Clinical Research - Tampa - Site Number: 840125
      • West Palm Beach、Florida、美国、33409
        • 主动,不招人
        • Palm Beach Medical & Research Center, Inc. - Site Number: 840165
    • Georgia
      • Columbus、Georgia、美国、31904
        • 主动,不招人
        • The Allergy Center at Brookstone - Site Number: 840114
    • Illinois
      • Chicago、Illinois、美国、60616
        • 主动,不招人
        • Next Innovation Clinical Research - Chicago - Site Number: 840159
    • Kentucky
      • Lexington、Kentucky、美国、40509
        • 主动,不招人
        • Bluegrass Allergy Care - Lexington - Site Number:840112
    • Maryland
      • Columbia、Maryland、美国、21045
        • 招聘中
        • Columbia Medical Practice - Site Number: 840172
      • Rockville、Maryland、美国、20854
        • 主动,不招人
        • Velocity Clinical Research - Rockville - Site Number: 840163
    • Michigan
      • Ann Arbor、Michigan、美国、48109
        • 招聘中
        • University of Michigan - Ann Arbor - Site Number: 840140
    • Montana
      • Missoula、Montana、美国、59808
        • 主动,不招人
        • Montana Medical Research - Site Number: 840137
    • Nebraska
      • Papillion、Nebraska、美国、68046
        • 主动,不招人
        • Primary Clinical Research, LLC - Papillion - Site Number: 840168
    • New Jersey
      • Sewell、New Jersey、美国、08080
        • 主动,不招人
        • MedCorps Asthma and Pulmonary Specialists LLC - Sewell - Site Number: 840136
    • New York
      • Cortland、New York、美国、13045
        • 主动,不招人
        • Finger Lakes Medical Research, PLLC - Site Number: 840155
      • New Windsor、New York、美国、12553
        • 主动,不招人
        • Mid Hudson Medical Research, PLLC - Site Number: 840139
      • New York、New York、美国、10029
        • 主动,不招人
        • Icahn School of Medicine at Mount Sinai - Center for Advanced Medicine - Site Number: 840119
    • North Carolina
      • Asheville、North Carolina、美国、28801
        • 主动,不招人
        • Allergy Partners of Western North Carolina - Site Number: 840131
      • Gastonia、North Carolina、美国、28054-7489
        • 主动,不招人
        • Clinical Research of Gastonia (CRG) - Site Number: 840160
      • Greenville、North Carolina、美国、27834-2849
        • 招聘中
        • East Carolina University Physicians - Pulmonary and Critical Care Medicine - Site Number: 840142
    • Ohio
      • Lima、Ohio、美国、45801
        • 主动,不招人
        • NexGen Research - Site Number: 840154
      • Toledo、Ohio、美国、43617
        • 主动,不招人
        • Toledo Institute of Clinical Research Inc - Site Number: 840105
    • Pennsylvania
      • Pittsburgh、Pennsylvania、美国、15241
        • 主动,不招人
        • Allergy and Clinical Immunology Associates - Site Number: 840127
    • South Carolina
      • Rock Hill、South Carolina、美国、29732
        • 主动,不招人
        • Clinical Research of Rock Hill - Site Number: 840115
    • Tennessee
      • Tennessee City、Tennessee、美国、30909
        • 主动,不招人
        • Allergy Associates, PA dba Allergy, Asthma and Sinus Center - Site Number: 840144
    • Texas
      • Dallas、Texas、美国、75235
        • 主动,不招人
        • Southwest Family Medicine Associates - Site Number: 840126
      • El Paso、Texas、美国、79902
        • 主动,不招人
        • El Paso Pulmonary Association (EPPA) - West El Paso - Site Number: 840108
      • Houston、Texas、美国、77090
        • 主动,不招人
        • Lumi Research - Site Number: 840156
      • Houston、Texas、美国、77099
        • 主动,不招人
        • Pioneer Research Solutions - Site Number: 840104
      • Hurst、Texas、美国、76054
        • 主动,不招人
        • Lumi Research - Hurst - Site Number: 840164
      • Tomball、Texas、美国、77081
        • 主动,不招人
        • DM Clinical - Tomball - Site Number: 840130
    • Washington
      • Bellingham、Washington、美国、98225
        • 主动,不招人
        • Bellingham Asthma, Allergy & Immunology Clinic - Site Number: 840138
      • Madrid、西班牙、28034
        • 招聘中
        • Investigational Site Number: 724408

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

6年 及以上 (孩子、成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

取样方法

非概率样本

研究人群

Enrollment into Part 1 is planned to achieve a balanced distribution of participants across participating regions, to the extent feasible. In addition, enrollment is intended to include pediatric participants, adolescents, and adults. Enrollment into Part 2 is planned to achieve a balanced distribution of participants across participating regions, to the extent feasible.

描述

Inclusion Criteria:

Applicable for Part 1 participants:

  • Age 6 years and older, at the time of signing the informed consent
  • Physician diagnosis of asthma for at least 12 months
  • Existing treatment with low, medium, or high dose ICS and other asthma therapies as reflected in GINA 2-5 steps
  • Participant or legally authorized representative (where applicable) has consented to participate

Applicable for Part 2 participants:

  • Age 18 years and older, at the time of signing the informed consent.
  • Physician diagnosis of asthma for at least 12 months
  • Existing treatment with low or medium ICS and other asthma therapies as reflected in GINA 2-4 steps
  • Participant or legally authorized representative (where applicable) has consented to participate
  • Participants must meet the criteria for at least one of the cohorts below:

A) Asthma control cohorts

  1. ACQ-5 >= 1.5
  2. ACQ-5 < 1.5 (B) Type-2 biomarker cohorts
  3. Elevated T2 biomarkers (B1: Type-2-high cohort)
  4. Low T2 biomarkers (B2: Type-2-low cohort)

Participants are excluded from the study if any of the following criteria apply (applicable for both Part 1 and Part 2 participants):

  • Current diagnosis of chronic obstructive pulmonary disease (COPD) or congestive heart failure
  • Participants with moderate/severe cognitive impairment.
  • Participants with moderate/severe cardiac disease.
  • Participants on immunosuppressive medication for a chronic condition.
  • Participation in other interventional and noninterventional clinical study (currently or in the past 3 months)

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:COHORT
  • 时间观点:PROSPECTIVE

队列和干预

团体/队列
干预/治疗
Part-1: Participants With Asthma

Participants receiving treatment with low-, medium-, or high-dose inhaled corticosteroids (ICS) and/or biologic therapies as part of standard of care (SoC) for the management of asthma in routine clinical practice.

Participant- and physician-reported outcomes will be collected per protocol. No Investigational Medicinal Product (IMP) administration.

Participant- and physician-reported outcomes, blood samples/lung tests and other optional assessments will be collected per protocol. No IMP administration.

Part-2: A1- Uncontrolled Asthma Cohort

Participants receiving SoC with Asthma Control Questionnaire-5 (ACQ-5) threshold of greater than or equal to (>=)1.5

Participant- and physician-reported outcomes will be collected per protocol. No Investigational Medicinal Product (IMP) administration.

Participant- and physician-reported outcomes, blood samples/lung tests and other optional assessments will be collected per protocol. No IMP administration.

Part-2: A2- Controlled Asthma Cohort

Participants receiving SoC with Asthma Control Questionnaire-5 (ACQ-5) threshold of less than (<)1.5

Participant- and physician-reported outcomes will be collected per protocol. No Investigational Medicinal Product (IMP) administration.

Participant- and physician-reported outcomes, blood samples/lung tests and other optional assessments will be collected per protocol. No IMP administration.

Part-2: B1- Type-2 (T2) High Asthma Cohort

Participants receiving SoC with elevated T2 biomarkers

Participant- and physician-reported outcomes will be collected per protocol. No Investigational Medicinal Product (IMP) administration.

Participant- and physician-reported outcomes, blood samples/lung tests and other optional assessments will be collected per protocol. No IMP administration.

Part-2: B2- Type-2 Low Asthma Cohort

Participants receiving SoC with low T2 biomarkers

Participant- and physician-reported outcomes will be collected per protocol. No Investigational Medicinal Product (IMP) administration.

Participant- and physician-reported outcomes, blood samples/lung tests and other optional assessments will be collected per protocol. No IMP administration.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Part 1: Descriptive Characterization of Participants With Asthma Across the Spectrum of Severities
大体时间:Part 1: At baseline

Descriptive Statistical Analyses may include sociodemographic and clinical characteristics, comorbidities, exacerbation history, medication burden, biomarkers and lung function.

Part 1: At baseline
Part 1: ACQ-5 Scores to Evaluate Characteristics of Participants With Asthma
大体时间:Part 1: At baseline

ACQ-5 is a 5-question survey. The five ACQ-5 questions are scored on a 6-point scale (0 = good control, 6 = poor control), and the overall score is the mean of the five responses. Participant's scores are then classified into three prescribed groups as having well-controlled asthma (score ≤ 0.75); partially controlled asthma (score 0.75-1.5), or not well controlled asthma (score >1.5). A change in ACQ-5 score of 0.5 is considered the minimal clinically important difference (MCID)

Part 1: At baseline
Part 1: Mini-Asthma Quality of Life Questionnaire (Mini-AQLQ) Scores to Evaluate Characteristics of Participants With Asthma
大体时间:Part 1: At baseline

The Asthma Quality of Life Questionnaire (AQLQ) includes 32 items, The mini-AQLQ is a reduced version of the AQLQ which includes 15 items. The questions correspond to 4 dimensions of health: symptoms (5 items), limitation of usual activities (4 items), emotional function (3 items) and environmental stimuli (3 items). The response options for each item are on an equidistant scale of 7 points, where 1 corresponds to the maximum disability and 7 to the absence of disability. Higher scores indicating better quality of life (less impairment) and lower scores indicating worse quality of life (greater impairment).

Part 1: At baseline
Part 1: Physician Global Assessment of Asthma Severity and Symptom Control
大体时间:Part 1: At baseline

Asthma severity, asthma control, and comorbidity will be assessed using three global impression of severity items: Physician Global Impression of Severity (PhGIS) - asthma severity. PhGIS - asthma control, and PhGIS - comorbidity.

Part 1: At baseline
Part 2: Descriptive Statistical Analysis of Difference in Asthma Symptom Control (ACQ-5) Between Part 2 Cohorts A1 and A2
大体时间:Part 2: At Weeks 52 and 104

Data on participant's asthma symptoms and control will be collected via the ACQ-5, 5-question survey. The five ACQ-5 questions are scored on a 6-point scale (0 = good control, 6 = poor control), and the overall score is the mean of the five responses. Participant's scores are then classified into three prescribed groups as having well-controlled asthma (score <=0.75); partially controlled asthma (score 0.75-1.5), or not well controlled asthma (score >1.5). A change in ACQ-5 score of 0.5 is considered the MCID.

Part 2: At Weeks 52 and 104
Part 2: Number of Participants Analyzed with Treatment Utilization Pattern between Part 2 Cohorts A1 and A2
大体时间:Part 2: At Weeks 52 and 104

Treatment utilization will include systemic corticosteroids (SCS), ICS, and short-acting beta agonists (SABA). Number of participants with various treatment utilization pattern will be assessed and reported.

Part 2: At Weeks 52 and 104
Part 2: Descriptive Statistical Analysis of Difference in Change in Pre-Bronchodilator Forced Expiratory Volume in 1 Second (Pre-BD FEV₁) between Part 2 Cohorts B1 and Cohort B2
大体时间:Part-2: At Weeks 52 and 104

Pre-BD FEV₁ is the forced expiratory volume in 1 second measured by spirometry prior to bronchodilator administration.

Part-2: At Weeks 52 and 104

次要结果测量

结果测量
措施说明
大体时间
第一部分:按人口统计学和临床特征分类的参与者人数
大体时间:第1部分:从研究入组前12个月开始
第1部分:从研究入组前12个月开始
第一部分:根据疾病负担、健康状况和治疗经历分组的参与者人数
大体时间:第1部分:从研究入组前12个月开始
第1部分:从研究入组前12个月开始
第1部分:按用药情况特征分类的参与者人数
大体时间:第一部分:从研究入组前12个月开始
第一部分:从研究入组前12个月开始
第1部分:按生活方式和环境影响因素划分的参与者人数
大体时间:第一部分:从研究登记前12个月开始
第一部分:从研究登记前12个月开始
Part 1: Number of Participants Characterised by Inhaled and Systemic Corticosteroid Use
大体时间:第1部分:从研究入组前12个月开始
第1部分:从研究入组前12个月开始
第1部分:按医疗资源利用(HCRU)特征区分的参与者数量
大体时间:第一部分:从研究入组前12个月开始
第一部分:从研究入组前12个月开始
第二部分:描述性特征分析,包括社会人口学特征、疾病特征及治疗史
大体时间:第二部分:基线时
第二部分:基线时
第2部分:第52周和第104周的年化急性加重率
大体时间:第2部分:在第52周和第104周
第2部分:在第52周和第104周
部分2:分析吸入性和全身性皮质类固醇负担变化的参与者数量
大体时间:第二部分:从基线至第104周
第二部分:从基线至第104周
第2部分:生物标志物水平的变化
大体时间:第二部分:在第52周和第104周
第二部分:在第52周和第104周
Part 1: Physician-Reported Outcomes to Characterize Physician Perspectives
大体时间:Part 1: From 12 months prior to study enrollment

The treatment preferences for participant profiles, an assessment of perceived disease burden on participants, an evaluation of barriers to optimal treatment, and treatment adherence and persistence will be collected from the main treating physician.

Part 1: From 12 months prior to study enrollment
Part 1: Change From Baseline in Patient Global Impression of Severity (PGIS) Score
大体时间:Part 1: From 12 months prior to study enrollment

The PGIS is a single question asking the participant to rate their severity and symptom control. The PGIS is a 5-point ordinal scale ranging from 1 (No symptoms) to 5 (Very severe symptoms). Higher scores indicate greater symptom severity.

Part 1: From 12 months prior to study enrollment
Part 1: Change From Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) Score
大体时间:Part 1: From 12 months prior to study enrollment

The WPAI-Asthma is an Asthma-specific, patient-reported measure of work absenteeism, work presenteeism (reduced productivity while working due to illness), total work productivity loss (absenteeism plus presenteeism), and overall activity impairment over the prior 7 days. The WPAI-Asthma questionnaire score represents the percentage of impairment, from 0 to 100%. Higher scores represent greater impairment and less productivity.

Part 1: From 12 months prior to study enrollment
Part 2: Changes From Baseline to Week 104 in Pre and Post Bronchodilator Forced Expiratory Volume in 1 Second (FEV1)
大体时间:Part 2: From baseline to week 52 and week 104

FEV1 will be measured in Liters. Change from baseline: mean of (value of observed FEV1 at treatment duration minus baseline value).

Part 2: From baseline to week 52 and week 104
Part 2: Number of Participants With Significant Changes in Asthma Treatment Patterns at Week 52 and Week 104
大体时间:Part 2: From baseline to week 52 and week 104

Changes in treatment patterns including use of SCS, ICS, other asthma therapies, and rescue medication. Treatment escalation (for example [e.g.], ICS dose changes, addition of asthma therapies, or biologic prescription), treatment adherence, and treatment persistence will be assessed from baseline to Week 52 and Week 104 in participants with Asthma.

Part 2: From baseline to week 52 and week 104
Part 2: Changes in Physician Global Assessment of Asthma Severity, Symptom Control and Comorbidities (PhGIS)
大体时间:Part 2: From baseline to week 52 and week 104

Asthma severity, asthma control, and comorbidity will be assessed using three global impression of severity items: PhGIS - asthma severity. PhGIS - asthma control, and PhGIS - comorbidity.

Part 2: From baseline to week 52 and week 104
Part 2: Number of Participants With Comorbidities and Burden of Comorbidities Based on the Participant Survey Using the PGIS scale
大体时间:Part 2: At Weeks 52 and 104

The PGIS is a single question asking the participant to rate their severity and symptom control. The PGIS is a 5-point ordinal scale ranging from 1 (No symptoms) to 5 (Very severe symptoms). Higher scores indicate greater symptom severity.

Part 2: At Weeks 52 and 104
Part 2: Number of Participants With Comorbidities and Burden of Comorbidities Based on the Physician Survey Using the PhGIS Scale
大体时间:Part 2: At Weeks 52 and 104

Asthma severity, asthma control, and comorbidity will be assessed using three global impression of severity items: PhGIS - asthma severity. PhGIS - asthma control, and PhGIS - comorbidity.

Part 2: At Weeks 52 and 104
Part 2: Changes in Physician-reported HCRU (Hospitalizations, Outpatient and Emergency Visits)
大体时间:Part 2: From baseline to week 52 and week 104

Data about HCRU associated with medical encounters will be collected by physicians from medical records. The data collected will include setting, department, type of specialist, the reasons and duration of hospitalizations, outpatient and emergency room (ER) visits.

Part 2: From baseline to week 52 and week 104
Part 2: Changes in Patient-Reported Outcomes to Characterize Disease Evolution
大体时间:Part 2: At Weeks 52 and 104

PROs used will include but not limited to ACQ-5, mini-AQLQ. ACQ-5 questions are scored on a 6-point scale (0 = good control, 6 = poor control), Mean of the five responses is the overall score. Scores are then classified into three groups as having well-controlled asthma (score <= 0.75); partially controlled asthma (score 0.75-1.5), or not well controlled asthma (score >1.5). AQLQ includes 32 items, The mini-AQLQ is a reduced version of the AQLQ which includes 15 items. The questions correspond to 4 dimensions of health: symptoms (5 items), limitation of usual activities (4 items), emotional function (3 items) and environmental stimuli (3 items). The response options for each item are on an equidistant scale of 7 points, where 1 corresponds to the maximum disability and 7 to the absence of disability.

Part 2: At Weeks 52 and 104
Part 2: Changes in Participant Survey Response
大体时间:Part 2: From baseline to week 52 and week 104

Participant survey collecting demographics, clinical characteristics, disease burden, health status, treatment experiences, medication use and burden, work and school impacts, lifestyle and environmental influences, impacts on daily life, PGIS for each comorbidity and burden of comorbidities, inhaled and systemic corticosteroid burden (frequency of use, routes of administration, treatment satisfaction), and HCRU office visits, hospitalizations, outpatient and emergency visits will be collected from medical records.

Part 2: From baseline to week 52 and week 104

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

合作者

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年4月1日

初级完成 (估计的)

2029年4月4日

研究完成 (估计的)

2029年4月4日

研究注册日期

首次提交

2026年3月31日

首先提交符合 QC 标准的

2026年4月21日

首次发布 (实际的)

2026年4月29日

研究记录更新

最后更新发布 (实际的)

2026年11月5日

上次提交的符合 QC 标准的更新

2026年11月4日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

其他研究编号

  • PIR21191
  • 2025-524916-13-00 (克蒂斯)
  • U1111-1336-5183 (注册表标识符:ICTRP)
  • 2025 (美国 NIH 拨款/合同)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅